• Natural Product Sciences
• /
• 제27권3호
• /
• pp.172-175
• /
• 2021

Sesbagrandiflorain F (1), a novel 2-arylbenzofuran, and two more 2-arylbenzofurans (2-3), were isolated from the stem bark of Sesbania grandiflora L. Based on information HRESIMS data, 1D, and 2D NMR spectra, the structure of 1 was fully assigned. Compounds 1-3 were tested for cytotoxicity in MCF-7 and HeLa cells. Compounds 1 and 3 showed moderate activity against MCF-7 cells with an IC₅₀ value of 2.68 and 4.08 ㎍/mL, respectively. Conversely, all of the isolates were inactive towards HeLa cells.

• Archives of Pharmacal Research
• /
• 제25권6호
• /
• pp.786-789
• /
• 2002

The total synthesis of a norneolignan isolated from Ratanhia, 5-(3-hydroxypropyl)-2-(2'-methoxy-4'-hydroxyphenyl)benzofuran (8), is described. The key steps contain the one-pot reaction for a 2-arylbenzofuran 6 from methyl 3-(4-hydroxyphenyl)propionate with 2-chloro-2-methylthio-(2'-methoxy-4'-acetoxy)acetophenone (5) in the presence of $ZnCl_2$, and reductive desulfurization of the resulting product 6.

• Archives of Pharmacal Research
• /
• 제23권5호
• /
• pp.438-440
• /
• 2000

The total synthesis of a demethoxy-egonol isolated from Styrax obassia, 5-(3-hydroxypropyl)-2-(3',4'-methylenedioxyphenyl)benzofuran (9), is described. The key steps involve the construction of a 2-arylbenzofuran skeleton 7 from methyl 3-(4-hydroxyphenyl)propionate with 2-chloro-2-methylthio-(3',4'-methylenedioxy) acetophenone (6) in the presence of ZnCl$_2$ and successive desulfurization of the resulting product 7.

• 대한화학회지
• /
• 제45권4호
• /
• pp.391-394
• /
• 2001

• Biomolecules & Therapeutics
• /
• 제28권4호
• /
• pp.344-353
• /
• 2020

This study aims to develop new potential therapeutic moracin M prodrugs acting on lung inflammatory disorders. Potential moracin M prodrugs (KW01-KW07) were chemically synthesized to obtain potent orally active derivatives, and their pharmacological activities against lung inflammation were, for the first time, examined in vivo using lipopolysaccharide (LPS)-induced acute lung injury model. In addition, the metabolism of KW02 was also investigated using microsomal stability test and pharmacokinetic study in rats. When orally administered, some of these compounds (30 mg/kg) showed higher inhibitory action against LPS-induced lung inflammation in mice compared to moracin M. Of them, 2-(3,5-bis((dimethylcarbamoyl)oxy)phenyl)benzofuran-6-yl acetate (KW02) showed potent and dose-dependent inhibitory effect on the same animal model of lung inflammation at 1, 3, and 10 mg/kg. This compound at 10 mg/kg also significantly reduced IL-1β concentration in the bronchoalveolar lavage fluid of the inflamed-lungs. KW02 was rapidly metabolized to 5-(6-hydroxybenzofuran-2-yl)-1,3-phenylene bis(dimethylcarbamate) (KW06) and moracin M when it was incubated with rat serum and liver microsome as expected. When KW02 was administered to rats via intravenous or oral route, KW06 was detected in the serum as a metabolite. Thus, it is concluded that KW02 has potent inhibitory action against LPS-induced lung inflammation. It could behave as a potential prodrug of moracin M to effectively treat lung inflammatory disorders.